title: Treatment results and prognostic factors for advanced squamous  cell carcinoma of the hypopharynx treated with concurrent  chemoradiotherapy.
abstract: OBJECTIVE
  The purpose of the study is to review our experience with concurrent chemoradiotherapy (CCRT) for patients with advanced resectable squamous cell carcinoma(SCC) of the hypopharynx and to evaluate the factors affecting survival and larynx preservation.
  
  
  METHODS
  Retrospective study.
  
  
  METHODS
  T he records of 102 patients with Stage III or IV resectable SCC of the hypopharynx treated with CCRT between January 1998 and August 2010 were reviewed. Of the 102 patients, 62 were treated with high dose regimens including cisplatin, 5-fluorouracil, methotrexate, leucovorin or docetaxel, cisplatin, and 5-fluorouracil. The remaining 40 were treated with low-dose regimens including carboplatin and uracil-tegafur, weekly docetaxel, or S-1. Radiotherapy was delivered 5 days a week using a single daily fraction of 1.8–2.0 Gray (Gy), to a total dose of 64.8–70.2 Gy. Overall survival (OS), disease-specific survival (DSS), and DSS with larynx preservation were estimated using Kaplan–Meier methods. The log-rank test and Cox proportional hazards regression were used to identify significant prognostic factors for OS, DSS, and DSS with larynx preservation.
  
  
  RESULTS
  The 5-year OS and DSS for all patients treated with CCRT were 51.3 and 64.3 %, respectively. The 5-year DSS with larynx preservation was 55.5 %. On multivariate analysis, the content of chemotherapy was a significant predictor of OS and DSS for patients undergoing CCRT ; N stage was a significant prognostic factor for DSS and larynx preservation.
  
  
  CONCLUSIONS
  T he treatment method including the indication for CCRT may be determined by the contents of the chemotherapy and the N stages of SCC of the hypopharynx.
authors.forename: Takahide
authors.initials: T
authors.lastname: Taguchi
authors.forename: Goshi
authors.initials: G
authors.lastname: Nishimura
authors.forename: Masahiro
authors.initials: M
authors.lastname: Takahashi
authors.forename: Masanori
authors.initials: M
authors.lastname: Komatsu
authors.forename: Daisuke
authors.initials: D
authors.lastname: Sano
authors.forename: Naoko
authors.initials: N
authors.lastname: Sakuma
authors.forename: Ken-ichiro
authors.initials: K
authors.lastname: Yabuki
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Arai
authors.forename: Hideaki
authors.initials: H
authors.lastname: Takahashi
authors.forename: Masaharu
authors.initials: M
authors.lastname: Hata
authors.forename: Izumi
authors.initials: I
authors.lastname: Koike
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Oridate
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D059248:Chemoradiotherapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D000077195:Squamous Cell Carcinoma of Head and Neck; D016019:Survival Analysis; D016896:Treatment Outcome